描述
Product Description
Anrikefon (CAS 2269511-95-5), also known as HSK21542, is a synthetic research compound that functions as a kappa opioid receptor (KOR) agonist. Opioid receptors (mu, delta, and kappa) are critical regulators of pain perception, reward processing, and stress responses. Unlike mu-opioid receptor agonists, which are associated with addictive liability, kappa receptor agonists are under investigation as alternative analgesics with reduced abuse potential.
Background and Significance
The opioid system plays a central role in modulating nociception and stress responses. While classical opioids such as morphine primarily activate the mu-opioid receptor (MOR), leading to strong analgesia but also dependence and tolerance, selective kappa receptor agonists like Anrikefon provide a different pharmacological profile. KOR agonists offer analgesia through distinct signaling pathways without the same level of euphoric reinforcement, making them highly valuable for research in non-addictive pain therapeutics.
Anrikefon has been optimized for selectivity, potency, and safety in experimental models, providing a reliable pharmacological tool for studying opioid receptor signaling, neurobiology, and pain physiology.
Chemical Properties and Research Utility
-
Compound Class: Synthetic peptide-based opioid receptor agonist
-
Primary Target: Kappa opioid receptor (KOR)
-
Effect: Analgesia, antinociception, and modulation of stress-related signaling
-
Research Applications: Pain physiology, opioid receptor pharmacology, neuropsychiatric disorders
Anrikefon provides unique advantages compared to other opioid receptor ligands, allowing researchers to explore kappa-specific signaling without significant mu-receptor-mediated confounding effects.
Product Specifications
Parameter | Details |
---|---|
Product Name | Anrikefon |
Synonyms | HSK21542, Kappa opioid receptor agonist |
CAS Number | 2269511-95-5 |
Molecular Formula | Not disclosed (synthetic peptide analog) |
Molecular Weight | Approximate, peptide-based |
Appearance | White to off-white lyophilized powder |
Purity | ≥98% (HPLC) |
Solubility | Soluble in water, PBS, and DMSO |
Stability | Stable for ≥24 months at –20°C |
Storage Conditions | Store at –20°C, avoid repeated freeze-thaw cycles |
GMP Compliance | Produced under GMP-certified manufacturing |
Applications | Pain research, opioid receptor pharmacology, CNS research |
Availability | Retail & bulk quantities |
Experimental Models | Rodent and non-human primate models of nociception and stress |
Safety Considerations | For laboratory research use only; not for human or veterinary use |
Mechanism of Action & Research Applications
Mechanism of Action
Anrikefon acts as a selective kappa opioid receptor agonist, binding to KORs located in the central and peripheral nervous system. Upon activation:
-
Analgesic Effect: KOR agonism reduces nociceptive transmission in the spinal cord and brain regions associated with pain perception.
-
Anti-Pruritic Effect: KOR activation reduces itch signaling, making it useful for dermatological pain/itch models.
-
Stress and Mood Modulation: KOR agonism regulates stress pathways in the hypothalamic-pituitary-adrenal (HPA) axis.
-
Reduced Abuse Potential: Unlike MOR agonists, KOR agonists lack strong reinforcing effects, lowering addiction liability in preclinical models.
Research Applications
-
Pain and Analgesia Studies
Anrikefon is used to study central and peripheral pain mechanisms, including neuropathic and inflammatory pain models. -
Opioid Receptor Pharmacology
Provides insights into KOR signaling pathways compared to mu- and delta-opioid receptor ligands. -
Addiction Research
Helps evaluate potential opioid analgesics with reduced risk of dependence. -
Stress and Neuropsychiatric Disorders
KOR signaling is implicated in stress, depression, and anxiety models, making Anrikefon a tool for CNS research. -
Drug Development Models
Supports the design of next-generation non-addictive analgesics and KOR-selective therapeutics.
Side Effects (For Reference in Research Models)
In laboratory research models, the following effects have been noted for KOR agonists such as Anrikefon:
-
Dysphoria or Mood Alterations: Some animal models report aversive behavioral responses.
-
Motor Impairment: High doses may affect locomotor activity.
-
Sedation: CNS depression has been observed in experimental studies.
-
Stress Response Changes: Prolonged exposure may alter stress hormone signaling.
-
Species-Specific Sensitivity: Effects may differ across rodent and primate models.
-
Tolerance with Chronic Use: Extended dosing may reduce analgesic efficacy over time.
Disclaimer
For laboratory research use only. Not for human or veterinary use.
Keywords
-
Anrikefon HSK21542
-
Kappa opioid receptor agonist peptide
-
Non-addictive analgesic research compound
-
GMP-grade opioid receptor agonist
-
Anrikefon pain research peptide
-
KOR agonist for CNS research
-
Anrikefon bulk supplier
-
Laboratory-grade kappa opioid agonist
-
Research use only opioid receptor ligand
评价
目前还没有评价